Research programme: radioisotope-based cancer therapeutics - Oncoinvent

Drug Profile

Research programme: radioisotope-based cancer therapeutics - Oncoinvent

Alternative Names: Radspherin™

Latest Information Update: 19 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oncoinvent
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Peritoneal cancer

Most Recent Events

  • 18 Jan 2017 Oncoinvent receives patent allowance for Radspherin™ in USA
  • 18 Jan 2017 Preclinical trials in Peritoneal cancer in Norway (Parenteral)
  • 20 May 2016 Preclinical trials in Cancer (Metastatic disease) in Norway (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top